As Esperion Therapeutics INC (ESPR) Stock Price Rose, Sabby Management LLC Raised Holding by $5.07 Million

Investors sentiment decreased to 0.95 in Q2 2018. Its down 0.55, from 1.5 in 2018Q1. It worsened, as 43 investors sold ESPR shares while 35 reduced holdings. 18 funds opened positions while 56 raised stakes. 26.84 million shares or 9.29% more from 24.56 million shares in 2018Q1 were reported. American Century Cos Inc has invested 0% in Esperion Therapeutics, Inc. (NASDAQ:ESPR). Hall Laurie J Trustee reported 80 shares. Natixis holds 0% in Esperion Therapeutics, Inc. (NASDAQ:ESPR) or 8,044 shares. Moreover, One Trading Limited Partnership has 0.01% invested in Esperion Therapeutics, Inc. (NASDAQ:ESPR). Nicholas Investment Prns Lp holds 0.21% in Esperion Therapeutics, Inc. (NASDAQ:ESPR) or 75,020 shares. Metropolitan Life Insur Company has invested 0% in Esperion Therapeutics, Inc. (NASDAQ:ESPR). Fmr Ltd Liability Corp invested in 0% or 922,979 shares. The Ontario – Canada-based Bancorporation Of Montreal Can has invested 0% in Esperion Therapeutics, Inc. (NASDAQ:ESPR). Swiss Bankshares has invested 0% in Esperion Therapeutics, Inc. (NASDAQ:ESPR). Retail Bank Of Mellon holds 0% or 111,584 shares in its portfolio. Rothschild Asset Management has invested 0.01% in Esperion Therapeutics, Inc. (NASDAQ:ESPR). Sg Americas Ltd invested in 0.01% or 27,319 shares. Pinnacle Assoc Limited has 0.18% invested in Esperion Therapeutics, Inc. (NASDAQ:ESPR). Wells Fargo And Com Mn has 450,158 shares. Wasatch Advisors reported 0.26% of its portfolio in Esperion Therapeutics, Inc. (NASDAQ:ESPR).

Sabby Management Llc increased its stake in Esperion Therapeutics Inc (ESPR) by 690.01% based on its latest 2018Q2 regulatory filing with the SEC. Sabby Management Llc bought 129,881 shares as the company’s stock rose 15.64% with the market. The hedge fund held 148,704 shares of the health care company at the end of 2018Q2, valued at $5.83M, up from 18,823 at the end of the previous reported quarter. Sabby Management Llc who had been investing in Esperion Therapeutics Inc for a number of months, seems to be bullish on the $1.38B market cap company. The stock decreased 4.84% or $2.62 during the last trading session, reaching $51.49. About 428,138 shares traded. Esperion Therapeutics, Inc. (NASDAQ:ESPR) has declined 8.71% since December 8, 2017 and is downtrending. It has underperformed by 24.33% the S&P500.

Sabby Management Llc, which manages about $835.79 million and $647.22M US Long portfolio, decreased its stake in Spdr S&P Biotech (Put) by 622 shares to 500 shares, valued at $4.76M in 2018Q2, according to the filing. It also reduced its holding in Astrazeneca Plc (Call) by 11,914 shares in the quarter, leaving it with 2,731 shares, and cut its stake in Astrazeneca Plc (Put).

More notable recent Esperion Therapeutics, Inc. (NASDAQ:ESPR) news were published by: Fool.com which released: “Here’s Why Esperion Therapeutics Dropped as Much as 36.9% Today – The Motley Fool” on May 02, 2018, also Nasdaq.com with their article: “Do Options Traders Know Something About Esperion (ESPR) Stock We Don’t? – Nasdaq” published on November 14, 2018, Streetinsider.com published: “Esperion Therapeutics (ESPR) Highlights Late-Breaking Oral Presentation of Final Study 3 Results (1002-046) of Bempedoic Acid – StreetInsider.com” on November 12, 2018. More interesting news about Esperion Therapeutics, Inc. (NASDAQ:ESPR) were released by: Seekingalpha.com and their article: “For Esperion, The Only Trial That Matters Is CLEAR Outcomes Due In 2022 – Seeking Alpha” published on May 25, 2018 as well as Seekingalpha.com‘s news article titled: “Esperion Therapeutics: Hold For PDUFA Date – Seeking Alpha” with publication date: September 25, 2018.

Esperion Therapeutics, Inc. (NASDAQ:ESPR) Ratings Coverage

Among 3 analysts covering Esperion Therapeutics (NASDAQ:ESPR), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. Esperion Therapeutics had 3 analyst reports since July 11, 2018 according to SRatingsIntel. As per Friday, August 17, the company rating was upgraded by Citigroup. The rating was downgraded by Northland Capital on Wednesday, July 11 to “Market Perform”.

Esperion Therapeutics, Inc. (NASDAQ:ESPR) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.